Navigation Links
Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
Date:10/10/2010

SAN FRANCISCO, CAOctober 10, 2010Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

More than 160 million people are infected throughout the world, and no vaccine is available to prevent further spread of the disease. Current treatments are not effective against the most common strains in the US and Europe. The study, published in the journal Nature Medicine, shows that the enzyme DGAT1 is a key factor in HCV infection. With several potential DGAT1 inhibitors already in the drug-development pipeline, a treatment for HCV may be possible in the near future.

"Our results reveal a potential 'Achilles heel' for HCV infection," said Melanie Ott, MD, PhD, senior author on the study. "Several DGAT1 inhibitors are already in early clinical trials to treat obesity-associated diseases. They might also work against HCV."

At first glance, the HCV lifecycle is fairly simple. The virus enters the cell. One large protein is produced and cut into several smaller viral enzymes and proteins that build the virus. The RNA genome is copied, and the new RNAs and structural proteins are used to make new virus particles that are released into the blood stream for to infect more cells. These processes were thought to occur at specialized membranes inside the cell. However, recently it has been shown that fat droplets are critically involved.

Fat droplets, which store fat in cells, have become a hot new topic in biology. DGAT1 is one of the enzymes that help to form fat droplets. The Gladstone team, led by Eva Herker, PhD, discovered that HCV infection and viral particle production are severely impaired in liver cells that lack DGAT1 activity.

"DGAT enzymes produce the fat that is stored in the droplets that are important for HCV replication, so we wondered if inhibiting those enzymes might disrupt the viral life cycle," said Dr. Herker. "We found that HCV specifically relies on one DGAT enzymes, DGAT1. When we inhibit DGAT1 with a drug, the liver still produces fat droplets through another DGAT enzyme but these droplets cannot be used by HCV."

The team sought to identify which step in the HCV lifecycle requires DGAT1. They found that DGAT1 interacts with one viral protein, the viral nucleocapsid core protein, required for viral particle assembly. The core protein normally associates with the surface of fat droplets but cannot do so when DGAT1 is inhibited or missing in infected cells.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstones Shinya Yamanaka wins Kyoto prize
2. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
3. Gladstones Shinya Yamanaka wins Lasker Award
4. Gladstone scientists identify key factors in heart cell creation
5. Gladstone scientists reveal key enzyme in fat absorption
6. Gladstone scientists reveal that fat synthesizing enzyme is key to healthy skin and hair
7. Scientists watch cell-shape process for first time
8. Studying illnesses caused by worms: Scientists are learning how immune cells communicate
9. Scientists trick bacteria with small molecules
10. DFG awards 4 young scientists 2010 Bernd Rendel Prize
11. Scripps Research scientists develop novel test that identifies river blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ -  Equicare Health Inc ., ... been recognized as one of the top 100 companies ... international listing that distinguishes the top digital health companies ... great step forward this year continually upgrading our product ... customer base and team," says Len Grenier , ...
(Date:11/30/2016)... Nov. 30, 2016   Merck , a leading ... entered into a set of agreements with Evotec AG, ... collection of genetic reagents such as CRISPR and shRNA ... expertise offers an accelerated pathway to explore and identify ... the identification of new targets, a process that can ...
(Date:11/30/2016)... ... November 30, 2016 , ... With growth rates averaging more than ... years and look forward to continuing their expansion in their new office space. The ... has been traditionally favoured by the creative industries, so Random42 Scientific Communication will fit ...
Breaking Biology Technology: